Last reviewed · How we verify
Cesol®
At a glance
| Generic name | Cesol® |
|---|---|
| Also known as | PZQ |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- L-PZQ ODT in Schistosoma Infected Children (PHASE3)
- Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni (PHASE2, PHASE3)
- Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide (PHASE1)
- Relative Bioavailability Study of Emodepside IR-tablets and Solution (PHASE1)
- Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers (PHASE1)
- Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years (PHASE1)
- Safety and Efficacy of Mirazid for Schistosomiasis Treatment (PHASE3)
- Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |